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Abstract
Type 1 diabetes (T1D) is characterized by an immuno-mediated progressive destruction of the pancreatic b cells. Due to the
ability of NK cells to kill target cells as well as to interact with antigen-presenting and T cells, it has been suggested that they
could be involved in one or multiple steps of the immune-mediated attack that leads to T1D. Abnormalities in the frequency
and activity of NK cells have been described both in animal models and patients with T1D. Some of these alterations are
linked to its onset while others seem to be a consequence of the disease. Here, we discuss the main characteristics of NK cells
and review the studies that investigated the role of NK cells in T1D, both in mouse models and humans.
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Introduction
Type 1 diabetes (T1D) is characterized by an
immuno-mediated progressive destruction of the
pancreatic b cells (Kelly et al. 2003). Although the
precise mechanisms involved in its pathogenesis are
still unclear, it is known that autoreactive T cells have
a central role in the process. Due to the ability of NK
cells to kill target cells as well as to interact with
antigen-presenting and T cells, it has been suggested
that they could be involved in one or multiple steps of
the immune-mediated attack that leads to T1D. Here,
we discuss the main characteristics of NK cells and
review the studies that investigated the role of NK cells
in T1D, both in mouse models and humans.
NK cells
NK cells are large granular lymphocytes that do not
express B or T cell receptors and participate in the
innate immune response. Besides playing important
roles in defence against malignancies and infectious
diseases, NK cells are implicated in the graft-versus-
host disease, the regulation of hematopoiesis and are
capable of interfering in the adaptative immune
response (Flodstrom et al. 2002). Under normal
circumstances, they are primarily located in the
peripheral blood, bone marrow, spleen and liver
(Moretta et al. 2002; French and Yokoyama 2004;
Sinkovics and Horvath 2005). In humans, NK cells
are identiﬁed by the lack of the surface marker CD3
and the presence of CD56 with or without CD16.
NK cells act through the cytotoxic destruction of
their target cells. Unlike cytolitic T lymphocytes, they
exert their effector function without the need for
previous in vitro or in vivo activation. This character-
istic makes them remarkably suited to mediate the ﬁrst
line of defence against pathogens, as part of the innate
immune response (Baxter and Smyth 2002; Colucci
et al. 2003). When activated, NK cells induce
apoptosis of the target cells mainly through the
exocytosis of perforin and granzyme. They also secrete
pro-inﬂammatory cytokines such as interferon gamma
(IFNg), tumor necrosis factor (TNF), granulocyte–
macrophage colony-stimulating factor (GM-CSF)
and macrophage inﬂammatory protein 1a and 1b
(Backstrom et al. 2004).
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molecules on the surface of these cells. These
molecules may be either inadequately present or
absent due to cell infection or its transformation. In
the ﬁrst situation, this could be due to non-self
molecules encoded by pathogens or, alternatively, self-
molecules only expressed in a higher frequency in
certain adverse conditions. The second scenario
implies the absence of molecules normally present
on the surface of the autologous cells, like MHC class
I. These alterations could render these cells suscep-
tible to NK lysis (Raulet 2004). Generally, this second
mechanism alone does not trigger cytotoxicity, unless
it is combined to the anomalous expression of other
molecules on the target cell surface.
There are receptors on the surface of the NK cells
that can trigger cell stimulation or inhibition. Brieﬂy,
these receptors are coupled with intra-cellular signal-
ling adapters that contain activation or inhibition sites
based on their tyrosine residues. These are called,
respectively, immunoreceptor tyrosine-based acti-
vation motifs (ITAM) e immune tyrosine based
inhibitory motifs (ITIM) (Lanier and Bakker 2000).
Two main categories of NK inhibitory receptors
were identiﬁed in humans: the heterodimer
CD94:NKG2A, speciﬁc for HLA E molecules; and
the killer cell immunoglobulin-like (KIR) receptors,
that recognize HLA A, B and C molecules. KIR
receptors, however, are not always inhibitory. They
belong to a diverse family of receptors, both
stimulatory or inhibitory, codiﬁed by genes in the
chromosome 19 and expressed mainly by NK cells,
but also by some subgroups of T lymphocytes (Vilches
and Parham 2002; Middleton et al. 2005). Based on
the combination of KIR genes, two major groups of
haplotypes can be deﬁned, A and B. While genes
encoding inhibitory receptors predominate in the
former, two or more activating KIR genes are present
in the latter (Slik et al. 2003).
NKG2D and natural cytotoxicity receptors (NCRs)
are the main NK activating receptors. NCRs (NKp30,
NKp44, NKp46 and NKp80) are expressed exclu-
sively in NK cells and belong to the superfamily of
immunoglobulins (Pende et al. 1999; Sivori et al.
1999; Moretta and Moretta 2004). Their ligands are
not completely deﬁned, but it is known that at least
part of them (NKp44 and NKp46) recognize viral
hemmaglutinins. Heparan sulphate proteoglycans
have also been shown to act as ligands for NKp46
and NKp30 (Arnon et al. 2001; Mandelboim et al.
2001; Bloushtain et al. 2004). The NKG2D receptor
is expressed by the majority of human NK cells, but
also in other lymphocytes such as CD8 þ .I ti s
codiﬁed by the NK receptor gene complex in
chromosome 12. Differently from the other NKG2
receptors, which are inhibitory and form dimers with
the receptor CD94, the receptor NKG2D is a
homodimer that recognizes a variety of ligands
induced by stress, such as non-classic HLA class I
molecules MICA and MICB, as well as ULBPs
(Raulet 2003; Andre et al. 2004).
Although numerous receptors have been implicated
in NK cells activation, it is not known if any speciﬁc
receptor alone is capable of triggering the NK effector
function by itself. A synergic interaction between
multiple receptors seems to be necessary for triggering
the cytotoxicity and cytokines production. Therefore,
NK cell function depends on the balance of various
signals from stimulatory and inhibitory receptors, as
well as the expression of their corresponding ligands
(Hoffman 1980).
NK cells in autoimmune diseases
Aproximately 5% of the population in the Western
countries are affected by autoimmune diseases
(Flodstrom et al. 2002). Although there is a strong
genetic component determining susceptibility to these
diseases, some kind of environmental factor is usually
also necessary to trigger their appearance. Under
normal conditions, self-tolerance mechanisms prevent
intra-thymic maturation and activation of autoreactive
lymphocytes, what is called central tolerance (Janeway
et al. 2005). However, a small proportion of the
autoreactive cells escapes from this process, undergoes
maturation and reaches the peripheral circulation. To
prevent the autologous cells against destruction by
these autoreactive cells, there are also peripheral
mechanisms that can prevent the action of these
autoreactive or even destroy them, what is known as
peripheral tolerance. When there is a failure in the
central or peripheral self-tolerance mechanisms,
immune reaction to self-antigens can occur, leading
to autoimmune diseases.
NK cells might have a direct inﬂuence in the
development of autoimmune diseases, destroying cells
in their target organs, or, alternatively, havean indirect
role, regulating the adaptative immune response (Kos
and Engeman 1996; Shi et al. 2000). This modulation
could occur in various steps of the autoimmune
response. Due to their potential to interact with
antigen-presenting cells (like dendritic cells), NK cells
could interfere in the priming of autoimmune
responses. They might also inﬂuence the downstream
response, as it is known that they can affect the
proliferation and generation of B and T autoreactive
lymphocytes. Although NK cells might prevent the
presentation of self-antigens by dendritic cells,
avoiding the autoimmune response, they also seem
to be necessary for the initiation of auto-reactive B
and/or T cell response (Sinkovics and Horvath 2005).
On the other hand, NK cells can also secrete cytokines
that supress B and T cell responses or even destroy
them (French and Yokoyama 2004).
Given their cytololytic ability, NK cells have been
potentially involved in the pathogenesis of diseases
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diseases. It has been shown that NK cells can kill
autologous cells (Hansson et al. 1981; Morse et al.
2001). However, under normal conditions, molecules
on the surface of the autologous cells, especially MHC
class I, engage inhibitory receptors on the surface of
NK cells preventing them from delivering a lytic
signal and making them self-tolerant. Loss of self-
tolerance can occur if an autologous cell loses the
expression of MHC class I (Flodstrom et al. 2002).
The exact mechanism involved in the development
of self-tolerance by the NK cells is not completely
understood.
NK cells have been identiﬁed in target organs of
patients suffering from autoimmune diseases (Flod-
strom et al. 2002). Although this phenomenon might
be explained solely by the migration of NK cells as
part of any inﬂammatory process, independently of
its cause, there is evidence that NK cells are capable
of attacking autologous cells (Hansson et al. 1981;
MacKay et al. 1986; Nakamura et al. 1990; Morse
et al. 2001) which may indicate that they could
contribute to the development of autoimmune cell
destruction. As infectious disease have been impli-
cated as potential triggers for many autoimmune
diseases and one of the main roles of NK cells is the
protection against infections, a link between NK
cells and autoimmune diseases would seem reason-
able. NK cells might either promote or suppress
autoimmune diseases triggered by infectious dis-
eases. By rapidly clearing the infection, NK cells
could limit the immune-mediated tissue damage
(Paya et al. 1989; Fairweather et al. 2001). On the
other hand, a vigorous attack towards infected
autologous cells could result in signiﬁcant destruc-
tion of the target tissues (Flodstrom et al. 2002),
which could lead to the release of self-antigens. As
the inﬂammatory milieu caused by the infection may
induce the priming of adaptative immune response,
this can cause to the activation of normally quiescent
autoreactive lymphocytes reacting to the recently
spread self-epitopes.
Curiously, several small studies during the 80s have
shown a reduced number and/or function of NK cells
in the peripheral blood of patients with autoimmune
diseases such as multiple sclerosis, rheumatoid
arthritis, Sjogren syndrome and T1D (Hoffman
1980; Herold et al. 1984; Negishi et al. 1986; Lorini
et al. 1994; French and Yokoyama 2004). In many
of these studies, however, NK cell frequency was
established based on non-speciﬁc markers that did not
exclude NKT or other cells from the counts. NKT
cells are Tregulatory cells involvedin the development
of peripheral tolerance that share some receptors with
NK cells but, differently from NK cells, present CD3
on their surface.
A reduced frequency or function of NK cells in the
peripheral blood of patientswith autoimmune diseases
could represent a primary defect involved in the
pathogenesis of the disease or a secondary effect of
the disease itself or its treatment. In many cases, the
treatment of autoimmune diseases includes corticos-
teroids. Although it has been shown recently that these
drugs may reduce NK killing capacity (Mavoungou
et al. 2005), studies in recently diagnosed patients
with SLE and dermatomyositis in whom corticoster-
oid treatment had not been started show that the
NK dysfunction cannot be attributed to the treatment
(Yabuhara et al. 1996; O’Gorman et al. 2002).
Although a deﬁciency of NK cells could be involved
in the appearance of autoimmune diseases in general,
interestingly, the main clinical characteristics of
patients with complete and selective NK cells
deﬁciency are not autoimmune diseases, but recurrent
infections, especially the ones caused by herpesvirus
(Biron et al. 1989). On the other hand, patients with
NK related lymphocytosis frequently present auto-
immune diseases (Tefferi et al. 1994).
Recently, it has been recognized that certain
expression patterns of activating and/or inhibitory
receptors on NK cells may be linked to the
development of autoimmune diseases. A predomi-
nance of KIR activating receptors over inhibitory ones
was reported in psoriatic arthritis (Martin et al. 2002).
An increased expression of MICA in the sinovium of
patients with reumathoid arthritis was also shown
(Groh et al. 2003).
NK cells in mouse models of type 1 diabetes
The two most intensively studied rodent models of
autoimmune T1D are the nonobese diabetic mouse
(NOD) and the BioBreeding (BB) rat. Both
develop autoimmune mediated destruction of the
pancreatic b cells after a variable period of insulitis
similarly to human T1D. These animal models have
been extremely important to help us elucidate the
mechanisms involved in the development of T1D. The
early stages of the disease process leading to T1D are
characterized by insulitis, followed by b cell destruc-
tion in the later stages (Kelly et al. 2003). When most
insulin-secreting cells are lost, T1D usually becomes
clinically evident. The rate of progression from
insulitis to T1D is variable and can range from a
rapid destruction with a very early onset of the disease
to a slow process with a late and quite often insidious
clinical presentation. The precise mechanisms
involved in the development of insulitis and its
progression to necrosis and massive b cell destruction
is still yet to be elucidated. Autoreactive T-cells have
been shown to have a critical role in this process
(Eisenbarth 1986). Although autoantibodies against
the major antigens related to T1D are produced, they
seem to be a consequence of b cell destruction and
a wide spread of antigens present on these cells
(Baekkeskov 1982).
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cells was suggested in the 80s. At that time, it was
shown that, in diabetes prone BB rat, splenic NK cells
were capable of destroying pancreatic islet cells in
these animals (MacKay et al. 1986; Koevary 1988;
Nakamura et al. 1990). More recently, the potential of
NK cells to destroy islet cells was also demonstrated in
NOD mice (Flodstrom et al. 2002). However, NK
cells do not seem to be essential for the development
of T1D, at least in animal models. Although the
depletion of NK cells prevented the development of
T1D in mice treated with streptozotocin (Maruyama
et al. 1991a) and cyclophosphamide (Maruyama et al.
1991b), it did not result in similar prevention in mice
that spontaneously develop T1D (Ellerman et al.
1993; Sobel et al. 1995) or in BB rats (Edouard et al.
1993; Ellerman et al. 1993). The role of NK cells in
the pathogenesis of T1D could be a modulation of the
intensity and aggressiveness of the b cell destructive
process. Indeed, Poirot et al. (2004) have demon-
strated a higher frequency of NK cells in the
pancreatic inﬁltrate of BDC 2.5 transgenic mice with
a B6.H-2
g7 genetic backgound, known to present a
rapid progression from insulitis to T1D, than in BDC
2.5 transgenic mice with a NOD genetic background,
which present innocuous insulitis with a rare and slow
progression of the disease a higher frequency of NK
cells in the pancreatic inﬁltrate of BDC2.5/B6.H-2
g7
transgenic mice. Flodstrom et al. (2002) suggested
that NK cells could have a particularly important
role in T1D induced by virus. According to this
hypothesis, pancreatic b cells could have an abnormal
response to IFN that would render them susceptible
to viral infections and subsequent cell death induced
by the NK cells. This could trigger T1D not only
directly, causing b cell lysis, but also indirectly, as in
genetic predisposed individuals the NK mediated
damage could contribute to the release of self-antigens
that could prime autoreactive T cells and trigger the
disease.
Systemic abnormalities of NK cells have also been
described in animal models for T1D. It has been
shown that diabetes-prone BB/W rats have an
increased frequency and activity of NK cells when
compared with diabetes resistant rats of the same
species (Woda and Biron 1986), although the opposite
has been observed when intestinal NK cells were
studied (Todd et al. 2004). Numeric and functional
abnormalities in NK cells have also been reported in
NOD mice and been implicated in the etiology of
T1D (Kataoka et al. 1983; Poulton et al. 2001;
Johansson et al. 2004). Poulton et al. (2001) have
found a decreased numbers of peripheral NK cells
in these animals with an increased frequency in the
bone marrow, suggesting that a defect in NK export
could be involved. Kataoka et al. (1983) described
a depression of natural killer activity in 12-week-old
NOD mice. A particularly interesting abnormality in
NOD mice is a deﬁcient activity of the receptor
NKG2D in NK cells. In these animals, upon
activation NK cells from NOD mice but not from
C57BL/6 mice expressed NKG2D ligands, which
resulted in downregulation of the receptor NKG2D. It
is not yet known whether this abnormality is involved
in the induction of diabetes in NOD mice (Ogasawara
et al. 2003). Interestingly, a study performed by the
same authors has shown that activation of NKG2D in
CD8 þ cells is essential for the progression from
insulitis to diabetes in NOD mice (Ogasawara et al.
2004).
NK cells in humans with type 1 diabetes
A few small studies in the 80s and 90s have shown a
reduction of the frequency of NK cells in the
peripheral blood in patients with T1D, especially in
the ones with recent onset (Chandy et al. 1984;
Herold et al. 1984; Pozzilli et al. 1984; Gupta et al.
1986; Wilson et al. 1986; Hussain et al. 1987). A few
authors, however, have found a numeric deﬁciency of
NK cells independently of the disease duration and
suggested that this abnormality could be persistent
and possibly genetically determined (Hussain et al.
1987). On the other hand other studies performed at
that time did not ﬁnd any abnormality in the
frequency of NK cells in the peripheral blood (Herold
et al. 1984; Scheinin et al. 1990). Two important
concerns with those early studies are the small
numbers of patients included and the use of non-
speciﬁc markers such as H25, Leu7 (CD57) and
Leu11a (CD16) (Scheinin et al. 1990; Baxter and
Smyth 2002) to identify the NK cells.H25 is no longer
available, but in any case bound to T cells in addition
to NK cells. While Leu 7 (CD57) is not only also
expressed in T cells but also absent on some NK cells,
Leu11a (CD16) is present on monocytes, macro-
phages and some granulocytes in addition to NK cells.
Recently, we have conﬁrmed with a larger sample and
more speciﬁc markers at the Joslin Diabetes Center
(Boston, MA) that patients with recently diagnosed
T1D have a slight reduction in the frequency of NK
cell in the peripheral blood when compared to controls
or patients with long-standing disease (Rodacki et al.
2006). However, the biological relevance of this
ﬁnding is questionable, since the difference was quite
modest. Nevertheless, this slight reduction could be
related to the existence of insulinopenia or, alterna-
tively, to a polarization of NK cells to the pancreas as a
contributing factor for the b-cell destruction.
Functional abnormalities have also been reported
in NK cells of patients with T1D. A reduced lytic
capacity, as determined by cytotoxicity assays, was
also reported in those earlier studies, both in recently
diagnosed patients and/or the ones with long-standing
T1D (Negishi et al. 1986; Lorini et al. 1994). As for
the numeric abnormalities, these results were not
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1987). In our recent analysis at the Joslin Diabetes
Center, there was a reduced surface expression of the
activating receptors NKp30 and NKp46 as well as
lower mRNA levels of IFNg and perforin in NK cells
of patients with long-standing T1D, but not in those
recently diagnosed, when compared to controls
without T1D. This indicates that there is a reduction
in the activity of NK cells in patients with long-
standing T1D but not in individuals with recent onset
disease, probably as a consequence of the disease
rather than a cause. The discrepancy between these
results might be related to the criteria used to deﬁne
the recent-onset group, varying from within 1 month
to up to 1 year after the diagnosis. In our cohort, all
recently diagnosed patients were tested within the ﬁrst
month of the disease.
The reduced activity of NK cells in patients with
long-standing T1D but not in those recently
diagnosed suggests that this could be a consequence
of the disease. Either a direct effect in the NK cells or
an abnormality that could interfere in their function
could be potentially implicated, such as an impaired
secretion of cytokines capable of interfering in NK
cells function or alteration in ligands to the NK cells
activating receptors. It is not yet known if the
abnormalities in NK cell function have any inﬂuence
in the risk of infectious diseases or neoplasias in
patients with T1D.
Lanier et al. had demonstrated that activated NK
cells in NOD mice displayed a low level of NKG2D.
We compared the expression of this receptor in
patients with T1D and controls and found a similarly
reduced expression of NKG2D in the ﬁrst group,
independently of the duration of the disease (Rodacki
et al. 2006). This suggests that there is a deﬁciency of
NKG2D expression not only in NOD mice but also in
humans with T1D. It is possible that this abnormality
is involved in the induction of T1D.
A few studies have evaluated KIR genes in patients
with T1D. While Van der Slik et al. (2003) have shown
a predominance of genes encoding activating KIR
genes in patients with T1D when compared to
controls. Nikitina-Zake et al. (2004) have demon-
strated that KIR2DL2, 2DS2 e 2DS3 were more
prevalent in patients with T1D than controls without
diabetes. These results suggest that certain KIR genes
might inﬂuence the susceptibility to T1D, which
would be reasonable since the KIR repertoire
determines self-tolerance in NK cells and also
inﬂuence the activity of T cells, both autoreactive
and regulatory (Vilches and Parham 2002). It is
possible that increased frequency of certain KIRs
might be associated with autoreactivity in T1D. In our
analysis, we conﬁrmed the association between
KIR2DS3 and T1D and also found interesting
associations between this gene and HLA class II
linked to T1D susceptibility. While HLA DR B1*03
was negatively associated with KIR2DS3, for HLA
DR B1*04 a positive association was found (Rodacki
et al. 2006). Combinations of HLA and KIR genes
have been linked with susceptibility of autoimmune
diseases (Rajagopalan and Long 2005).
Conclusion
Abnormalities in the frequency and activity of NK
cells have been described both in animal models and
patients with T1D. Some of these alterations are
linked to its onset while others seem to be a
consequence of the disease. The elucidation of the
exact role of NK cells in the pathogenesis of T1D is
important in order to explore whether possible related
immune interventions may affect the risk of T1D or
delay its age of presentation. It is also important to
clarify if NK abnormalities are involved in the risk of
infections or neoplasia in patients with T1D and if any
intervention can be used to correct this problem.
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